Regeneron forges CAR-T R&D partnership with bluebird bioDeal combines Regeneron’s receptor tech with CAR-T biotech’s expertise Share XRegeneron forges CAR-T R&D partnership with bluebird biohttps://pharmaphorum.com/news/regeneron-forges-car-t-rd-partnership-with-bluebird-bio/
Spectacular results for bluebird’s gene therapy in thalassemiaPatients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird Share XSpectacular results for bluebird’s gene therapy in thalassemiahttps://pharmaphorum.com/news/spectacular-results-for-bluebirds-gene-therapy-in-thalassemia/
Long-term CAR-T data dazzles at ASHGilead and Novartis CAR-Ts steal the show at ASH Share XLong-term CAR-T data dazzles at ASHhttps://pharmaphorum.com/news/long-term-car-t-data-dazzles-ash/
Scotland’s TC BioPharm joins bluebird to develop next-gen CAR-TUS cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T Share XScotland’s TC BioPharm joins bluebird to develop next-gen CAR-Thttps://pharmaphorum.com/news/scotlands-tc-biopharma-joins-bluebird-develop-next-gen-car-t/
More good news for Bluebird Bio with CALD gene therapyBluebird Bio has presented encouraging data from its gene therapy treatment for the rare condition, cerebral adrenoleukodystrophy (CALD). The Share XMore good news for Bluebird Bio with CALD gene therapyhttps://pharmaphorum.com/news/good-news-bluebird-bio-cald-gene-therapy/